Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Trph-222, a Novel Anti-CD22 Antibody Drug Conjugate (ADC), Has Signficant Anti-Tumor Activity in NHL Xenografts and Is Well Tolerated in Non-Human Primates

Ann Maclaren, PhD BS, Nancy Levin, PhD, Henry Lowman, PhD, Mohit Trikha, PhD

Blood (2017) 130 (Supplement 1): 4105.

https://doi.org/10.1182/blood.V130.Suppl_1.4105.4105

Published: 2017

Journal Articles

Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study

Andrew Spencer, Simon Harrison, MBBS MRCP(UK) FRCPath(UK) FRACP PhD, Jacob P. Laubach, MD, Jeffrey Zonder, MD, Ashraf Z Badros, MD, Krystal Bergin, Amit Khot, MD, Todd Zimmerman, MD, Kenneth C. Anderson, MD, Ann MacLaren, PhD, Steven D Reich, MD, Mohit Trikha, PhD, Paul G. Richardson, MD

Blood (2016) 128 (22): 3326.

https://doi.org/10.1182/blood.V128.22.3326.3326

Published: 2016

Journal Articles

Marizomib for CNS-Multiple Myeloma

Ashraf Z Badros, MD, Zeba Singh, MD, Binod Dhakal, MDMS, Young Kwok, MD, Ann MacLaren, PhD, Paul G. Richardson, MD, Mohit Trikha, PhD, Hari Parameswaran, MD

Blood (2016) 128 (22): 2118.

https://doi.org/10.1182/blood.V128.22.2118.2118

Published: 2016

Journal Articles

Lumiliximab Triggers Apoptosis Mechanisms in CLL Cells through the Inhibition of PI3-K/Akt Pathway.

Medhat Shehata, Susanne Schnabl, Elena Ponath, Stefanie Tauber, Dita Demirtas, Martin Hilgarth, Martin Bilban, Sigrun Badrnya, Karin Fleiss, Josef D. Schwarzmeier, Alexander Gaiger, Rainer Hubmann, Christoph C Zielinski, Steve Hughes, Ann Maclaren, Ulrich Jaeger

Blood (2009) 114 (22): 2371.

https://doi.org/10.1182/blood.V114.22.2371.2371

Published: 2009

Journal Articles

Lumiliximab, An Apoptosis Sensitizer to Multiple CLL Therapeutic Agents

Ann Maclaren, Amy Trauernicht, Lizbeth Nguyen, Karen McLachlan

Blood (2008) 112 (11): 4209.

https://doi.org/10.1182/blood.V112.11.4209.4209

Published: 2008

NARROW

Trph-222, a Novel Anti-CD22 Antibody Drug Conjugate (ADC), Has Signficant Anti-Tumor Activity in NHL Xenografts and Is Well Tolerated in Non-Human Primates

Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study

Marizomib for CNS-Multiple Myeloma

Lumiliximab Triggers Apoptosis Mechanisms in CLL Cells through the Inhibition of PI3-K/Akt Pathway.

Lumiliximab, An Apoptosis Sensitizer to Multiple CLL Therapeutic Agents

Email alerts

ASH Publications

American Society of Hematology

Trph-222, a Novel Anti-CD22 Antibody Drug Conjugate (ADC), Has Signficant Anti-Tumor Activity in NHL Xenografts and Is Well Tolerated in Non-Human Primates

Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study

Marizomib for CNS-Multiple Myeloma

Lumiliximab Triggers Apoptosis Mechanisms in CLL Cells through the Inhibition of PI3-K/Akt Pathway.

Lumiliximab, An Apoptosis Sensitizer to Multiple CLL Therapeutic Agents

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only